Biosimilars

Health By Ed Silverman

Virtual Event: The evolving landscape for biosimilars

Health By Michelle Andrews — Kaiser Health News

Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch

First Opinion By Gillian Woollett

The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means

Pharmalot By Ed Silverman

FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?

Pharmalot By Ed Silverman

Once again, the viability of the U.S. biosimilar market is thrown into question

Pharmalot By Ed Silverman

In a petition, Boehringer warns FDA its definition of ‘strength’ threatens biosimilar competition

Pharmalot By Ed Silverman

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Pharmalot By Ed Silverman

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Pharmalot By Ed Silverman

Large employers could have saved money if more biosimilars had been prescribed

Pharmalot By Ed Silverman

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

Business By Matthew Herper

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

Pharmalot By Ed Silverman

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Politics By Lev Facher

Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation

Pharmalot By Ed Silverman

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

Pharmalot By Ed Silverman

More hospital drug spending is going toward cancer immunotherapies

Pharmalot By Ed Silverman

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

First Opinion By Juliana Reed

Some bipartisan support for biosimilars is good. More would be better

First Opinion By Jessica Sagers and Peter Kolchinsky

Booker-Sanders-Harris drug affordability bureau could be brilliant

Pharmalot By Ed Silverman

Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill

First Opinion By Jonathan Kimball

Trade agreement drug monopoly is obsolete given faster, better drug discovery

Pharmalot By Ed Silverman

Pharmalittle: New records show drug makers’ opioid push; Senate bill would cap Medicare drug price hikes

Pharmalot By Ed Silverman

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

Pharmalot By Ed Silverman

Pharmalittle: Democrats eye negotiating for all drug plans; feds want part of Oklahoma settlement with Purdue

First Opinion By Hillel P. Cohen and Dorothy McCabe

Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions

Pharmalot By Ed Silverman

Most Read

FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug

Three steps toward creating a functioning U.S. biosimilars market

AbbVie accuses a company of recruiting an employee in order to steal Humira secrets

Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs

Tiny Denmark saved lots of money on biosimilar Humira, while Americans are still paying big bucks

Biosimilars could disappear if the Supreme Court overturns the ACA

Five years on, biosimilars need support from all health care players

From bench to bedside, biologics require excellence at every stage

All Coverage

Virtual Event: The evolving landscape for biosimilars

Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch

The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means

FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?

Once again, the viability of the U.S. biosimilar market is thrown into question

In a petition, Boehringer warns FDA its definition of ‘strength’ threatens biosimilar competition

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Large employers could have saved money if more biosimilars had been prescribed

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

More hospital drug spending is going toward cancer immunotherapies

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

Some bipartisan support for biosimilars is good. More would be better

Booker-Sanders-Harris drug affordability bureau could be brilliant

Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill

Trade agreement drug monopoly is obsolete given faster, better drug discovery

Pharmalittle: New records show drug makers’ opioid push; Senate bill would cap Medicare drug price hikes

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

Pharmalittle: Democrats eye negotiating for all drug plans; feds want part of Oklahoma settlement with Purdue

Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions

FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed